Arch Biopartners Inc.
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
55.6M
P/E Ratio
-
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.
Healthcare
Biotechnology
TSXV
Key Financial Metrics
-
Revenue
-1.6M
Net Income
-
EPS (Diluted)
-1.6M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-1.3M
Returns & Efficiency
Return on Assets (ROA)
-1485.5%
Return on Equity (ROE)
-
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
104,530
Total Debt
2.5M
Debt to Equity
-
Current Ratio
0.03
Company Info
| Industry | Biotechnology |
| HQ | Toronto, Canada |
| Fiscal Year End | 1759190400 |
| Currency | CAD |
| Website | www.archbiopartners.com |
Peers
Bausch + Lomb Corporation
BLCO.TO
7.9B
P/E: --
Bausch Health Companies Inc.
BHC.TO
2.5B
P/E: 12.0
Extendicare Inc.
EXE.TO
2.5B
P/E: 23.7
Sienna Senior Living Inc.
SIA.TO
2.2B
P/E: 53.2
Cronos Group Inc.
CRON.TO
1.4B
P/E: 24.1
Tilray Brands, Inc.
TLRY.TO
1.2B
P/E: --
WELL Health Technologies Corp.
WELL.TO
1.1B
P/E: --
Knight Therapeutics Inc.
GUD.TO
631.8M
P/E: --
Insider Activity
Sentiment
Bullish
Shares Bought
2,828,493
Shares Sold
0
Total Transactions
59
SEDAR+ Filings
View All Filings13
Quarterly Reports
11
MD&A
69
News Releases
10
Material Changes
10
Governance
25
Certifications
12
Other
Interactive Charts
Company Profile
General Information
| Company Name | Arch Biopartners Inc. |
| Ticker | ARCH.V |
| Exchange | TSXV |
| Sector | Healthcare |
| Industry | Biotechnology |
| Headquarters | Toronto, Canada |
| Fiscal Year End | 1759190400 |
| Currency | CAD |
| Website | www.archbiopartners.com |
Financial Summary
| Market Cap | 55.6M |
| Revenue | N/A |
| Net Income | -1.6M |
| P/E Ratio | N/A |
| EPS (Diluted) | N/A |
| Net Margin | N/A |
| ROE | N/A |
| Dividend Yield | N/A |
Business Description
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.